Surgery doesn't cure Crohn's disease, and inflammation can continue to cause GI damage. Learn about testing to detect ...
aTaub Faculty of Computer Science, Technion-Israel Institute of Technology, Haifa, Israel bFaculty of Electrical and Computer Engineering, Technion-Israel Institute of Technology, Haifa, Israel ...
Ten years after tailored radiotherapy (RT) for breast cancer, fewer than 3% of patients had locoregional recurrences (LRR), ...
Morning Overview on MSN
Triple pre-surgery combo therapy may boost immunity in sarcoma
A triple-drug regimen combining two immunotherapy agents with radiation before surgery appears to activate immune defenses ...
The firm has dosed the first patient in a China-based study testing JSKN016 in participants who have failed two or more prior treatments.
Ultrasensitive ctDNA testing distinguishes patients with very different risks for recurrence — but it remains to be seen whether acting on the results can improve their outcomes.
In this episode of The OncoloGIST, breast cancer oncologist and clinical researcher Dr Paolo Tarantino of Dana-Farber Cancer Institute reflects on how antibody-drug conjugates (AD ...
Alphamab Oncology (stock code: 9966.HK) today announced that the first patient has been dosed in a phase III clinical study (JSKN016-301) evaluating JSKN016, a novel TROP2/HER3 bispecific ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated ...
Abstract: Neural networks have become increasingly popular in recent years due to their ability to efficiently solve a wide range of complex problems, including computer vision, machine translation, ...
Dear Doctors: This might be a long shot, but I was diagnosed with triple negative breast cancer, had a lumpectomy with clear margins and had a recurrence six months later. I am struggling with the ...
Frontline antibody-drug conjugates boost progression-free survival in metastatic triple-negative breast cancer, showing early overall survival gains and expanding options. In an interview with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results